ESR1 and invasive lobular breast carcinoma: Invasive lobular breast carcinomas (LBCs), which account for up to 15% of all invasive breast cancers (BC), are almost always estrogen-positive (ER, coded by the ESR1 gene) and lacking HER2 amplification and as such are treated with endocrine therapy (ET) [1].